Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 2/20 | 0.49 |
| ▸ | LMNA | P02545 | 2/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.42 |
| ▸ | PKM | P14618 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | POLB | P06746 | 3/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2908214 | 0.89 | ALDH1A1 (0.47) | HTTLMNAALDH1A1 | |
| SCHEMBL2903285 | 0.87 | LMNA (0.50) | HTTLMNAMEN1KMT2AALDH1A1 | |
| SCHEMBL2910357 | 0.84 | SMN1; SMN2 (0.52) | HTTLMNAMEN1KMT2AALDH1A1 | |
| SCHEMBL2905409 | 0.84 | MEN1 (0.61) | HTTLMNAMEN1KMT2AALDH1A1 | |
| SCHEMBL2908712 | 0.84 | ALDH1A1 (0.50) | HTTLMNAMEN1KMT2AALDH1A1 | |
| SCHEMBL2905713 | 0.83 | ALDH1A1 (0.46) | HTTALDH1A1SMN1; SMN2SIGMAR1KDM4E | |
| SCHEMBL2906206 | 0.79 | ALDH1A1 (0.48) | HTTLMNAMEN1KMT2AALDH1A1 | |
| SCHEMBL2906383 | 0.78 | MAPT (0.53) | HTTLMNAMEN1KMT2AALDH1A1 | |
| SCHEMBL2904033 | 0.78 | SIGMAR1 (0.54) | HTTMEN1KMT2ASIGMAR1POLB | |
| SCHEMBL4384007 | 0.77 | ALDH1A1 (0.46) | HTTLMNAMEN1KMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120232097-A1 | CINNAMOYL-PIPERAZINE DERIVATIVES AND THEIR USE AS PAR-1 ANTAGONISTS | PEREZ MICHEL (FR) | 2012-09-13 | — | — | US | claimed |
| EP-2041104-B1 | CINNAMOYL-PIPERAZINE DERIVATIVES AND THEIR USE AS PAR- I ANTAGONISTS | PF MEDICAMENT (FR) | 2010-08-18 | — | — | EP | claimed |
| US-20090176803-A1 | CINNAMOYL-PIPERAZINE DERIVATIVES AND THEIR USE AS PAR-1 ANTAGONISTS | PIERRE FABRE MEDICAMENT (FR) | 2009-07-09 | — | — | US | claimed |
| EP-2041104-B1 | CINNAMOYL-PIPERAZINE DERIVATIVES AND THEIR USE AS PAR- I ANTAGONISTS | PF MEDICAMENT (FR) | 2010-08-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090176803-A1 | CINNAMOYL-PIPERAZINE DERIVATIVES AND THEIR USE AS PAR-1 ANTAGONISTS | F2R, F2RL1, F2RL3 | HTT 2817/4885LMNA 1615/4885MEN1 1701/4885 |
| US-20120232097-A1 | CINNAMOYL-PIPERAZINE DERIVATIVES AND THEIR USE AS PAR-1 ANTAGONISTS | F2R, F2RL1, F2RL3 | HTT 2817/4885LMNA 1615/4885MEN1 1701/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.